The Poultry Vaccines Market Size was valued at USD 1.92 billion in 2023 and is projected to grow from USD 2.05 Billion in 2023 to USD 3.32 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 6.18% during the forecast period (2024 - 2032). Increased awareness levels regarding animal vaccination and rising meat consumptionare the key market drivers enhancing market growth.
Source Secondary Research, Primary Research, MRFR Database, and Analyst Review
Elanco has joined hands with Bill and Melinda Gates Foundation to develop and produce new poultry vaccines for Africa in January 2024.
Boehringer Ingelheim International GmbH launched Ingelvac® CEV HVT+IBD, a combination vaccine for Newcastle Disease and Infectious Bronchitis in poultry in February 2024.
Hester Biosciences Limited signed a memorandum of understanding (MoU) with the International Livestock Research Institute (ILRI) to develop new poultry vaccines for Africa by August 2023.
Vaxxinova International BV entered into an agreement with China Animal Health and Food Safety Administration (CAHSA) on its Marek’s disease vaccine, HVT-IBD vectored vaccine in July 2023.
In December 2023, Venkys India released Vencovac™; this was part of a collaboration venture between it and Hester Biosciences that culminated in the development of an entirely new range of poultry vaccines.
Increasing research activities associated with poultry vaccines are driving market growth.
The growing R&D activities by the major market players for launching poultry vaccines to treat diseases and growing product approvals are expected to increase the market's growth during the forecast period. For instance, Venkys India provides a huge range of poultry vaccines, including the Salmonella polyvalent inactivated vaccine used to prevent and control salmonellosis in breeders, layers, and broilers. OILVAX EDS-76 is also a part of the portfolio of KM Biologics and is very effective against egg drop syndrome. This factor leads to the growth of the market CAGR.
Additionally,Several companies operating in the poultry vaccine market are focused on launching new technological solutions to boost their position. For instance, Boehringer Ingelheim, a Germany-based pharmaceutical company, launched the VAXXITEK HVT+IBD+ND vaccine to protect poultry from three types of diseases in 2020. VAXXITEK HVT+IBD+ND boosts a solid immune foundation and improves protection against infectious bursal diseases (classic and variant kinds), Marek's, and Newcastle's diseases.Moreover, increasing vaccine innovation, cost-effective animal health expenditure, rising demand for poultry vaccination, poultry-derived food products, rising technological advancement, increasing prevalence of zoonotic disease, increasing poultry population, a rising government initiative in poultry treatment, and increasing vaccination programs by leading industries. The factor that restrains the market growth of poultry vaccines is - increasing the cost of vaccines, increasing acceptance of vegetarian food, decreasing production of advanced vaccines, and increasing investment in animal health. These factors drive the Poultry Vaccines market revenue.
The Poultry Vaccines market segmentation, based on diseases, includes infectious bronchitis and Marek's disease. The infectious bronchitis segment dominated the market due to the high prevalence of infectious bronchitis in poultry and the increasing demand for poultry meat and eggs, driving the growth of the poultry vaccine market.
Figure1 Poultry Vaccines Market, by Diseases, 2023 & 2032 (USD billion)
Source Secondary Research, Primary Research, MRFR Database, and Analyst Review
Based on technology, the market segments of Poultry Vaccines includes toxoid, recombinant, inactivated, and live attenuated vaccines. The live attenuated vaccines segment dominated the market due to the effectiveness of live attenuated vaccines in providing long-lasting protection against a wide range of pathogens in poultry. These vaccines are also cost-effective.
Based on dosage form, the market segmentation of Poultry Vaccines includes duct, liquid, and freeze-dried vaccines. The freeze-dried vaccines segment dominated the market because Freeze-drying removes the water from the vaccine, which helps preserve its potency and efficacy.
By Region, the study provides market insights into North America, Europe, Asia-Pacific, and the Rest of the World. The North American poultry vaccines market will dominate this market; increased awareness levels regarding animal vaccination and rising meat consumptionwill boost the market growth in this Region.
Further, the major countries studied in the market report are The U.S., Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 2 POULTRY VACCINES MARKET SHARE BY REGION 2022 (%)
Source Secondary Research, Primary Research, MRFR Database, and Analyst Review
Europe's Poultry Vaccines market accounts for the second-largest market share due to the presence of key players, growing initiatives against using antimicrobials in animals, and rising concerns over zoonoses. Further, the German market of Poultry Vaccines held the largest market share, and the UK market of Poultry Vaccines was the fastest-growing market in the European Region.
The Asia-Pacific Poultry Vaccines Market is expected to grow at the fastest CAGR from 2024 to 2032. This is dueto the increasing awareness regarding poultry vaccines and a surge in vaccination awareness programs. Other factors include rising government initiatives and rapid improvement in animal husbandry practices. Moreover, China’s market of Poultry Vaccines held the largest market share, and the Indian market of Poultry Vaccines was the fastest-growing market in the Asia-Pacific region.
Poultry Vaccines Key Market Players& Competitive Insights
Leading market players are investing heavily in research and development in order to expand their product lines, which will help the market of Poultry Vaccines to grow even more. Market participants are also undertaking various strategic activities to expand their footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. The poultry vaccines industry must offer cost-effective items to expand and survive in a more competitive and rising market climate.
Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the Poultry Vaccines industry to benefit clients and increase the market sector. The Poultry Vaccines industry has offered some of the most significant medical advantages in recent years. Major players in the market of Poultry Vaccines, including Boehringer Ingelheim, Elanco, MSD & Co., Zoetis Inc, Ceva Animal Health Inc., Phibro Animal Health Corporation, Virbac, Hipra, Venkys, Biovet, Anicon GmbH, and others, are attempting to increase market demand by investing in research and development operations.
Bimeda is an international developer, manufacturer, and marketer of veterinary pharmaceuticals and animal care products. In addition to distributing Bimeda branded products in over seventy countries worldwide, Bimeda also manufactures private labels for distributors, agents, and international companies.Bimeda has 9 manufacturing facilities based in Ireland, the UK, France, Canada, the US, Brazil, and China. The company employs over 800 employees worldwide and has its headquarters in Carrickmines, Dublin, Ireland. Bimeda's American headquarters are in Chicago, Illinois.Bimeda is focused on providing a comprehensive, customer-driven service, selling consistently high-quality products at a market-conscious price level.Bimeda, an Ireland-based developer, manufacturer, and marketer of veterinary pharmaceuticals and animal care products, acquired Afrivet for an undisclosed amount. With this acquisition, Bimeda will have the broadest footprint of animal health companies on the African continent. Afrivet is a South Africa-based manufacturer of poultry vaccines.
Boehringer Ingelheim is working on breakthrough therapies that transform lives today and for future generations. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since Boehringer Ingelheim takes a long-term perspective. Over 52,000 employees serve over 130 markets in three business areas, Human Pharma, Animal Health and Biopharmaceutical Contract Manufacturing.Boehringer Ingelheim launched the VAXXITEK HVT+IBD+ND vaccine to protect poultry against Marek's Disease, Newcastle Disease, and Infectious Bursal Disease (classic and variant types). Boehringer Ingelheim will produce VAXXITEK HVT+IBD+ND from its site, which develops more than 60 billion doses of poultry vaccine annually for use in the U.S. and over 60 other countries.
Key Companies in the poultry vaccines market include
Poultry Vaccines Industry Developments
August 2022:Bimeda, an Ireland-based developer, manufacturer, and marketer of veterinary pharmaceuticals and animal care products, acquired Afrivet for an undisclosed amount. With this acquisition, Bimeda will have the broadest footprint of animal health companies on the African continent. Afrivet is a South Africa-based manufacturer of poultry vaccines.
December 2021:The Indian antibody producer Immuno-intelligent Limited has presented another goat pox immunization that helps check goat pox illness. A live, weakened antibody is to be allowed at 90 days old enough of the creature and afterward allowed again consistently with a portion pace of 1 ml, which is to be regulated subcutaneously.
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)